Sodium Bicarbonate 8.4% Solution for Injection: Intravenous infusion according to the treatment algorithm. Infusion starts with 100ml/hr until a pH of 7.30 - 7.35 and a Base Excess of ≥ 0 is reached. Then, infusion is reduced to 25ml/hr and maintained for 5 hours. After 5 hours, infusion is titrated to a pH of \>7.30.
Balanced crystalloid solution: Intravenous infusion according to the treatment algorithm. Infusion starts with 100ml/hr until a pH of 7.30 - 7.35 and a Base Excess of ≥ 0 is reached. Then, infusion is reduced to 25ml/hr and maintained for 5 hours. After 5 hours, infusion is titrated to a pH of \>7.30.
Study summary
The study investigates whether sodium bicarbonate is able to reduce the occurrence of major adverse kidney events on day 90 (MAKE90) in critically ill patients with metabolic acidosis and acute kidney injury (AKI). While its efficacy in this context has been suggested in a subgroup analysis of the BICAR-ICU trial it has not been confirmed in a double-blinded randomized controlled trial to date.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Adult ≥ 18 years
2. Critically ill patients (requiring treatment on an ICU or IMC)
3. Metabolic acidosis, defined as all of the following:
1. Arterial pH ≤7.25
2. PaCO2 \< 6.5kPa (\<49 mmHg)
3. Standard bicarbonate ≤20 mmol/L
4. Standard Base Excess \<-2
4. AKI stage 2 or 3 of the KDIGO classification
5. Written informed consent of the patient or legal representative or authorized representative or emergency inclusion (according to Article 35 EU-Regulation 536/2014)
Exclusion Criteria:
1. Pregnant or breastfeeding patients
2. Respiratory acidosis (acute or chronic) \[dynamic, and if corrected, patient may be reconsidered for the trial\]
3. Patients on KRT, or KRT immediately indicated and treating clinician(s) unwilling to defer
4. Deemed unsuitable for KRT
5. High output stoma/ileostomy
6. Percutaneous biliary drainage
7. End stage kidney failure defined as documented eGFR \<15ml/min/1.73m 2 prior to onset of this acute illness or end stage kidney disease (ESKD) on dialysis
8. Known renal tubular acidosis
9. Diabetic ketoacidosis
10. High anion gap acid poisoning (e.g. polyethylene glycol (PEG), aspirin, methanol)
11. Symptomatic hypocalcaemia (Ionized calcium \<1.05 mmol/L)\[dynamic, and if corrected, patient may be reconsidered for the trial\]
12. Hypernatremia (plasma sodium \>150 mmol/L)\[dynamic, and if corrected, patient may be reconsidered for the trial\]
13. Severe hypokalemia (potassium \<3.0 mmol/L)\[dynamic, and if corrected, patient may be reconsidered for the trial\]
14. Death perceived as imminent
15. Known hypersensitivity to sodium bicarbonate or EDTA (Disodiumedetate)
16. Previously randomized into ESCALATE
Primary outcome measure(s)
MAKE90 (consisting of mortality, dialysis within 90 days, persistent renal dysfunction (defined as serum creatinine ≥ 2x compared to baseline value at day 90) — 90 days after randomization
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.